136 related articles for article (PubMed ID: 7970996)
1. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
McGaurn SP; Davis LE; Krawczeniuk MM; Murphy JD; Jacobs ML; Norwood WI; Clancy RR
Pediatrics; 1994 Dec; 94(6 Pt 1):820-3. PubMed ID: 7970996
[TBL] [Abstract][Full Text] [Related]
2. [A study on treatment of hyperuricemia--effects and kinetics of allopurinol and oxipurinol].
Hosoya T; Ichida K; Tabe A; Sakai O
Ryumachi; 1991 Feb; 31(1):28-35. PubMed ID: 1857993
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol metabolism in a patient with xanthine oxidase deficiency.
Yamanaka H; Nishioka K; Suzuki T; Kohno K
Ann Rheum Dis; 1983 Dec; 42(6):684-6. PubMed ID: 6689118
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry.
Lartigue-Mattei C; Chabard JL; Ristori JM; Bussiere JL; Bargnoux H; Petit J; Berger JA
Fundam Clin Pharmacol; 1991; 5(7):621-33. PubMed ID: 1778540
[TBL] [Abstract][Full Text] [Related]
5. Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage.
Das DK; Engelman RM; Clement R; Otani H; Prasad MR; Rao PS
Biochem Biophys Res Commun; 1987 Oct; 148(1):314-9. PubMed ID: 2823807
[TBL] [Abstract][Full Text] [Related]
6. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia (author's transl)].
Dunky A; Nitsche V; Eberl R
Wien Klin Wochenschr; 1981 Jan; 93(2):65-8. PubMed ID: 7245774
[TBL] [Abstract][Full Text] [Related]
8. Role of purines and xanthine oxidase in reperfusion injury in perfused rat liver.
Zhong Z; Lemasters JJ; Thurman RG
J Pharmacol Exp Ther; 1989 Aug; 250(2):470-5. PubMed ID: 2547932
[TBL] [Abstract][Full Text] [Related]
9. Plasma oxipurinol concentrations during allopurinol therapy.
Emmerson BT; Gordon RB; Cross M; Thomson DB
Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
[TBL] [Abstract][Full Text] [Related]
10. Xanthine oxidase inhibition does not limit canine infarct size.
Werns SW; Grum CM; Ventura A; Hahn RA; Ho PP; Towner RD; Fantone JC; Schork MA; Lucchesi BR
Circulation; 1991 Mar; 83(3):995-1005. PubMed ID: 1999047
[TBL] [Abstract][Full Text] [Related]
11. Improved survival in intestinal ischemia by allopurinol not related to xanthine-oxidase inhibition.
Garcia Garcia J; Martin Rollan C; Refoyo Enrinquez MA; Holgado Madruga M; Mariño Hernandez E; Macias Nuñez JF; Gomez Alonso A
J Surg Res; 1990 Feb; 48(2):144-6. PubMed ID: 2304342
[TBL] [Abstract][Full Text] [Related]
12. Cerebral uric acid, xanthine, and hypoxanthine after ischemia: the effect of allopurinol.
Nihei H; Kanemitsu H; Tamura A; Oka H; Sano K
Neurosurgery; 1989 Oct; 25(4):613-7. PubMed ID: 2797398
[TBL] [Abstract][Full Text] [Related]
13. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical.
Spector T
Biochem Pharmacol; 1988 Jan; 37(2):349-52. PubMed ID: 2829916
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of xanthine oxidase by 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine.
Spector T; Hall WW; Porter DJ; Lambe CU; Nelson DJ; Krenitsky TA
Biochem Pharmacol; 1989 Dec; 38(23):4315-20. PubMed ID: 2557043
[TBL] [Abstract][Full Text] [Related]
15. Reversed-phase liquid-chromatographic determination of purine compounds in serum applied to studies of hypouricemia.
Kojima T; Nishina T; Kitamura M; Kamatani N; Nishioka K
Clin Chem; 1986 Feb; 32(2):287-90. PubMed ID: 3943189
[TBL] [Abstract][Full Text] [Related]
16. Effect of allopurinol on caffeine disposition in man.
Grant DM; Tang BK; Campbell ME; Kalow W
Br J Clin Pharmacol; 1986 Apr; 21(4):454-8. PubMed ID: 3754760
[TBL] [Abstract][Full Text] [Related]
17. Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300.
Schneider HJ; Brundig P; Balogh A; Traeger A; Stein G; Fünfstück R
Int Urol Nephrol; 1983; 15(2):121-9. PubMed ID: 6688800
[TBL] [Abstract][Full Text] [Related]
18. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.
Day RO; Miners J; Birkett DJ; Graham GG; Whitehead A
Br J Clin Pharmacol; 1988 Oct; 26(4):429-34. PubMed ID: 3190993
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol kinetics after massive overdosage.
Ferner RE; Simmonds HA; Bateman DN
Hum Toxicol; 1988 May; 7(3):293-4. PubMed ID: 3391630
[TBL] [Abstract][Full Text] [Related]
20. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
